Bhattacharya, S. D., Irina S.
Idler, Judith Rauen,
Allegra, D., Mertens,
D. (2011), In-vivo
quantification of primary microRNA processing by Drosha with a
luciferase based
system, Biochem Biophys Res Commun, 406:4: 501-505
Bhattacharya,
N., Diener, Idler, Barth, Rauen, Habermann,
Zenz, Möller, Döhner, Stilgenbauer, Mertens,
D. (2011). Non-malignant B cells and chronic
lymphocytic leukemia cells induce a pro-survival phenotype in CD14+
cells from
the peripheral blood. Leukemia,
25:4: 722-726, IF 8.296
Winkler,
D., C. Schneider, M. Zucknick, D. Bogelein, K.
Schulze, T. Zenz, J. Mohr, A. Philippen, H. Huber, A. Buhler, A.
Habermann, A.
Benner, H. Dohner, S. Stilgenbauer and D. Mertens
(2010). Protein expression analysis of
chronic lymphocytic leukemia defines the effect of genetic aberrations
and
uncovers a correlation of CDK4, P27 and P53 with hierarchical risk. Haematologica,
95:11: 1880-1888, IF 6.416
Zenz,
T., D. Mertens,
R. Kuppers, H. Dohner and S. Stilgenbauer (2010). From pathogenesis to treatment of chronic
lymphocytic leukaemia. Nat
Rev Cancer 10:1: 37-50, IF 29.538
31.
Bhattacharya, S. D., Irina S. Idler, Judith
Rauen,
30. Allegra,
D., Mertens, D. (2011), In-vivo
quantification of primary microRNA
processing by Drosha with a luciferase based system, Biochem
Biophys Res
Commun, 406:4: 501-505
29. Wittig-Blaich,
L. A. K., Thorsten Eismann,
Melanie Bewerunge-, P. K. Hudler, Eva Winkler, Wolfgang S.L. Strauss,
Raimund
Hibst, Rudolf and M. S. Steiner, Daniel Mertens,
Holger Sültmann, Rainer Wittig (2011), Prostate matrix
restores
AKT-phosphorylation and rescues loss of adhesion in
hepsin-overexpressing PC3
prostate cancer cells, Neoplasia, in press
28. Bhattacharya, N.,
Diener, Idler, Barth, Rauen, Habermann, Zenz, Möller,
Döhner, Stilgenbauer, Mertens,
D. (2011). Non-malignant B cells and chronic lymphocytic
leukemia
cells induce a pro-survival phenotype in CD14+ cells from the
peripheral blood.
Leukemia,
25:4: 722-726, IF 8.296
27. Winkler, D., C.
Schneider, M. Zucknick, D. Bogelein, K. Schulze, T. Zenz, J. Mohr, A.
Philippen, H. Huber, A. Buhler, A. Habermann, A. Benner, H. Dohner, S.
Stilgenbauer and D. Mertens (2010).
Protein expression analysis of chronic lymphocytic leukemia defines the
effect
of genetic aberrations and uncovers a correlation of CDK4, P27 and P53
with
hierarchical risk. Haematologica, 95:11: 1880-1888,
IF 6.416
26. Mohr, H., Fuge,
Eldering, Buehler, Winkler, Volden, Kater, Mertens,
te Raa, Doehner, Stilgenbauer, Zenz (2010). DNA damage induced transcriptional programme in
CLL: biological and
diagnostic implications of functional p53 testing. Blood
117:5: 1622-1632, IF 10.555
25. Philippen, A., S.
Diener, T. Zenz, H. Dohner, S. Stilgenbauer and D. Mertens
(2010). SYK carries no
activating point mutations in patients with chronic lymphocytic
leukaemia
(CLL). Br
J Haematol
150:5: 633-636, IF
4.597
24. Bhattacharya, N.,
A. Sarno, I. S. Idler, M. Fuhrer, T. Zenz, H. Dohner, S. Stilgenbauer
and D. Mertens (2010). High-throughput detection of nuclear
factor-kappaB
activity using a sensitive oligo-based chemiluminescent enzyme-linked
immunosorbent assay. Int
J Cancer
127:2: 404-411, IF 4.722
23. Giannopoulos, K.,
D. Mertens, A. Buhler, T. F. Barth,
I. Idler, P. Moller, A. Krober, J. Greiner, S. Chocholska, A.
Dmoszynska, J.
Rolinski, H. Dohner, S. Stilgenbauer and M. Schmitt (2009). The candidate immunotherapeutical target, the
receptor
for hyaluronic acid-mediated motility, is associated with proliferation
and
shows prognostic value in B-cell chronic lymphocytic leukemia. Leukemia
23:3: 519-527, IF
8.296
22. Zenz,
T., J. Mohr, E. Eldering, A. P. Kater,
A. Buhler, D. Kienle, D. Winkler, J. Durig, M. H. van Oers, D. Mertens, H. Dohner and S. Stilgenbauer
(2009). miR-34a as part of the resistance network in chronic
lymphocytic
leukemia. Blood
113:16: 3801-3808, IF
10.555
21. Zenz, T., J.
Mohr, J. Edelmann, A. Sarno, P. Hoth, M. Heuberger, H. Helfrich, D. Mertens, H. Dohner and S. Stilgenbauer
(2009). Treatment resistance in chronic
lymphocytic leukemia: the role of the p53 pathway. Leuk
Lymphoma
50:3: 510-513, IF 2.397
20. Zenz, T., S.
Habe, T. Denzel, J. Mohr, D. Winkler, A. Buhler, A. Sarno, S. Groner,
D. Mertens, R. Busch, M. Hallek, H.
Dohner
and S. Stilgenbauer (2009). Detailed analysis
of p53 pathway defects in fludarabine-refractory chronic lymphocytic
leukemia
(CLL): dissecting the contribution of 17p deletion, TP53 mutation,
p53-p21
dysfunction, and miR34a in a prospective clinical trial. Blood
114:13: 2589-2597,
IF 10.555
19. Loeder, S., T.
Zenz, A. Schnaiter, D. Mertens, D.
Winkler, H. Dohner, K. M. Debatin, S. Stilgenbauer and S. Fulda (2009).
A novel paradigm to trigger apoptosis in
chronic
lymphocytic leukemia. Cancer Res 69:23: 8977-8986, IF 7.543
18. Idler, I., K.
Giannopoulos, T. Zenz, N. Bhattacharya, M. Nothing, H. Dohner, S.
Stilgenbauer
and D. Mertens (2009). Lenalidomide treatment of chronic lymphocytic
leukaemia patients reduces regulatory T cells and induces Th17 T helper
cells. Br
J Haematol
148:6: 948-950, IF 4.597
17. Tschuch, C., A.
Schulz, A. Pscherer, W. Werft, A. Benner, A. Hotz-Wagenblatt, L. S.
Barrionuevo, P. Lichter and D. Mertens
(2008). Off-target effects of siRNA specific
for GFP. BMC Mol Biol 9: 60, IF
2.848
16. Prowatke,
I., F. Devens, A. Benner, E. F.
Grone, D. Mertens, H. J. Grone, P.
Lichter and S. Joos (2007). Expression analysis of imbalanced genes in
prostate
carcinoma using tissue microarrays. Br
J Cancer
96:1: 82-88, IF 4.346
15. Kalla, C., M. O.
Scheuermann, I. Kube, M. Schlotter, D. Mertens,
H. Dohner, S. Stilgenbauer and P. Lichter (2007). Analysis of 11q22-q23
deletion target genes in B-cell chronic lymphocytic leukaemia: evidence
for a
pathogenic role of NPAT, CUL5, and PPP2R1B. Eur
J Cancer
43:8: 1328-1335, IF 4.121
14. Wolf, S., D. Mertens, A. Pscherer, P. Schroeter, D.
Winkler, H. J. Grone, C. Hofele, K. Hemminki, R. Kumar, G. Steineck, H.
Dohner,
S. Stilgenbauer and P. Lichter (2006). Ala228 variant of trail receptor 1 affecting
the ligand binding site is
associated with chronic lymphocytic leukemia, mantle cell lymphoma,
prostate
cancer, head and neck squamous cell carcinoma and bladder cancer. Int
J Cancer
118:7: 1831-1835, IF 4.722
13. Mertens,
D., S. Wolf, C. Tschuch, C.
Mund, D. Kienle, S. Ohl, P. Schroeter, F. Lyko, H. Dohner, S.
Stilgenbauer and
P. Lichter (2006). Allelic silencing at the
tumor-suppressor locus 13q14.3 suggests an epigenetic tumor-suppressor
mechanism. Proc Natl Acad Sci U S A 103:20:
7741-7746, IF 9.432
12. Mannherz, O., D. Mertens, M. Hahn and P. Lichter (2006).
Functional screening for proapoptotic genes by
reverse transfection cell array technology. Genomics
87:5: 665-672, 3.327
11. Kienle, D., A.
Benner, A. Krober, D. Winkler, D. Mertens,
A. Buhler, T. Seiler, U. Jager, P. Lichter, H. Dohner and S.
Stilgenbauer
(2006). Distinct gene expression patterns in
chronic lymphocytic leukemia defined by usage of specific VH genes. Blood
107:5: 2090-2093, IF 10.555
10. Henrich, K. O., M.
Fischer, D. Mertens, A. Benner, R.
Wiedemeyer, B. Brors, A. Oberthuer, F. Berthold, J. S. Wei, J. Khan, M.
Schwab
and F. Westermann (2006). Reduced expression
of CAMTA1 correlates with adverse outcome in neuroblastoma patients. Clin
Cancer Res
12:1: 131-138, IF 6.747
9. Adamowicz, M., B.
Radlwimmer, R. J. Rieker, D. Mertens,
M. Schwarzbach, P. Schraml, A. Benner, P. Lichter, G. Mechtersheimer
and S.
Joos (2006). Frequent amplifications and abundant expression of TRIO,
NKD2, and
IRX2 in soft tissue sarcomas. Genes Chromosomes Cancer
45:9: 829-838, IF 3.858
8. Kienle, D. L., C.
Korz, B. Hosch, A. Benner, D. Mertens,
A. Habermann, A. Krober, U. Jager, P. Lichter, H. Dohner and S.
Stilgenbauer
(2005). Evidence for distinct
pathomechanisms in genetic subgroups of chronic lymphocytic leukemia
revealed
by quantitative expression analysis of cell cycle, activation, and
apoptosis-associated genes. J
Clin Oncol
23:16: 3780-3792, IF 17.793
7. Kalla, C., H.
Nentwich, M. Schlotter, D. Mertens,
K. Wildenberger, H. Dohner, S. Stilgenbauer and P. Lichter (2005).
Translocation t(X;11)(q13;q23) in B-cell chronic lymphocytic leukemia
disrupts
two novel genes. Genes Chromosomes Cancer 42:2:
128-143, IF 3.858
6. Mertens,
D., S. Wolf, P.
Schroeter, C. Schaffner, H. Dohner, S. Stilgenbauer and P. Lichter
(2002). Down-regulation of candidate tumor suppressor
genes
within chromosome band 13q14.3 is independent of the DNA methylation
pattern in
B-cell chronic lymphocytic leukemia. Blood
99:11: 4116-4121, IF 10.555
5. Korz, C., A.
Pscherer, A. Benner, D. Mertens, C.
Schaffner, E. Leupolt, H. Dohner, S. Stilgenbauer and P. Lichter
(2002).
Evidence for distinct pathomechanisms in B-cell chronic lymphocytic
leukemia
and mantle cell lymphoma by quantitative expression analysis of cell cycle and
apoptosis-associated genes. Blood
99:12: 4554-4561, IF
10.555
4. Wolf, S., D. Mertens, C. Schaffner, C. Korz, H.
Dohner, S. Stilgenbauer and P. Lichter (2001). B-cell neoplasia
associated gene
with multiple splicing (BCMS): the candidate B-CLL gene on 13q14
comprises more
than 560 kb covering all critical regions. Hum
Mol Genet
10:12: 1275-1285.,
IF 7.386
3. Bullinger, L., E.
Leupolt, C. Schaffner, D. Mertens,
M. Bentz, P. Lichter, H. Dohner and S. Stilgenbauer (2000). BCL10 is
not the
gene inactivated by mutation in the 1p22 deletion region in mantle cell
lymphoma. Leukemia 14:8: 1490-1492, IF
8.296
2. Mertens,
D., S. Wolf, L. Bullinger, S.
Ohl, C. Schaffner, H. Dohner, S. Stilgenbauer and P. Lichter (2000).
BCMSUN, a
candidate gene for B-cell chronic lymphocytic leukemia and mantle-cell
lymphoma, has an independently expressed homolog on 1p22- p31, BCMSUN-like. Int
J Cancer
88:5: 692-697., IF 4.722
1.
Lammer, C., S. Wagerer, R. Saffrich, D. Mertens,
W. Ansorge and I. Hoffmann
(1998). The cdc25B phosphatase is essential
for the G2/M phase transition in human cells. J Cell Sci
111 (Pt 16):
2445-2453, IF 6.144
11. Schnaiter, A., Mertens, D., Stilgenbauer, S. (2011), Genetics of Chronic Lymphocytic Leukemia, Clinics in Laboratory Medicine, in press.
10. Giannopoulos, K., Mertens, D., Stilgenbauer, S. (2011), Treating chronic lymphocytic leukemia with Thalidomide and Lenalidomide, Current Opinion in Pharmacotherapy, in press.
9. Mertens, D., Bullinger, L., Stilgenbauer, S. (2011), Chronic Lymphocytic Leukemia - Genomics Lead the Way, Haematologica, 96(10):1402-5.
8. Stilgenbauer, S., Mertens, D. (2011), Toward chemotherapy-free treatment of CLL, Blood, 118(13), 3451-2.
7. Idler,
N. B., Döhner, H., Stilgenbauer, S., Mertens, D. (2011), Immune modulatory agents
in hematopoietic
malignancies, Cancer Treatment Reviews, 37 Suppl 1:
S2-7.
6. Zenz,
T., D. Mertens, H. Dohner and S.
Stilgenbauer (2011), Importance of genetics in chronic lymphocytic
leukemia, Blood
Rev 25:3: 131-137
5.
Zenz, T., D. Mertens,
R. Kuppers, H. Dohner and S. Stilgenbauer (2010). From pathogenesis to treatment of chronic
lymphocytic leukaemia. Nat
Rev Cancer 10:1: 37-50, IF 29.538
4.
Zenz, T., D. Mertens
and S. Stilgenbauer (2010). Biological
diversity and risk-adapted treatment of chronic lymphocytic leukemia. Haematologica
95:9: 1441-1443, IF 6.416
3.
Zenz, T., S. Frohling, D. Mertens,
H. Dohner and S. Stilgenbauer (2010). Moving from prognostic to predictive factors in
chronic lymphocytic leukaemia (CLL). Best
Pract Res Clin Haematol
23:1: 71-84, IF 3.134
2. Mertens, D.,
A. Philippen, M. Ruppel, D. Allegra, N. Bhattacharya, C. Tschuch, S.
Wolf, I.
Idler, T. Zenz and S. Stilgenbauer (2009). Chronic lymphocytic leukemia and 13q14: miRs
and more. Leuk Lymphoma
50:3: 502-505, IF 2.397
1.
Zenz, T., D. Mertens,
H. Dohner and S. Stilgenbauer (2008). Molecular
diagnostics in chronic lymphocytic leukemia - pathogenetic and clinical
implications. Leuk
Lymphoma
49:5: 864-873, IF 2.397